O36.1131 Maternal care for Anti-A sensitization, third trimester, fetus 1

Name of the Condition

• Maternal care for Anti-A sensitization, third trimester, fetus 1
• ICD Code: O36.1131

Summary

This condition involves medical care and monitoring provided to a pregnant woman who has developed antibodies against the A antigen on red blood cells during the third trimester of pregnancy, specifically for a singleton fetus. The care focuses on managing the potential risks to the fetus and ensuring maternal health, particularly addressing the risk of hemolytic disease of the fetus and newborn (HDFN).

Causes

Anti-A sensitization occurs when an individual with type O blood (lacking A antigens) is exposed to A-positive blood, triggering the production of anti-A antibodies. In pregnancy, this exposure may happen during a previous pregnancy with an A-positive fetus, blood transfusion, or events causing fetal-maternal blood mixing. These antibodies can cross the placenta and attack the red blood cells of an A-positive fetus.

Risk Factors

• Previous pregnancy with an A-positive fetus
• Blood transfusion with A-positive blood
• Abdominal trauma during pregnancy
• Invasive prenatal procedures (e.g., amniocentesis)
• Prior miscarriage or ectopic pregnancy involving an A-positive fetus

Symptoms

• Often asymptomatic in the mother
• Fetal anemia, jaundice, or hydrops fetalis in severe cases
• Elevated bilirubin levels in the newborn

Diagnosis

Diagnosis involves blood typing and antibody screening to detect anti-A antibodies. Doppler ultrasound may be used to assess fetal blood flow and anemia. Additional monitoring, such as serial ultrasounds or fetal blood sampling, may be performed to evaluate fetal well-being.

Treatment Options

Treatment may include close monitoring of the pregnancy, administration of intravenous immunoglobulin (IVIG), or intrauterine transfusions if severe fetal anemia is detected. Delivery timing may be adjusted based on fetal status and maternal health.

Prognosis and Follow-Up

With appropriate monitoring and intervention, outcomes for both mother and fetus are generally favorable. Follow-up care includes postpartum monitoring of the newborn for signs of anemia or jaundice and ongoing evaluation of maternal antibody levels.

Complications

Potential complications include fetal anemia, hydrops fetalis, preterm birth, or neonatal jaundice requiring treatment. Severe cases may lead to fetal demise.

Lifestyle & Prevention

Prevention focuses on avoiding unnecessary exposure to A-positive blood and minimizing risks of fetal-maternal blood mixing. Prenatal care should include blood type screening and antibody testing early in pregnancy.

When to Seek Professional Help

Seek medical attention if there are signs of fetal distress, such as reduced fetal movement, or if the mother experiences symptoms like abdominal pain or bleeding. Prompt evaluation is critical for managing potential complications.

Tips for Medical Coders

Document the trimester (third) and fetus count (singleton) to support code assignment. Ensure clinical documentation specifies anti-A sensitization and any associated monitoring or interventions. Verify that the code aligns with the timing and context of care provided.